Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury?

JGH Open

Volumn 2, Issue 4, 2018, Pages 152-157

  Teschke, Rolf ^a   Wolff, Albrecht ^b   Eickhoff, Axel ^a   Danan, Gaby ^c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Pharmacovigilance Consultancy   (France)

Author keywords

dietary supplements; green tea extract; Herbalife; Hydroxycut; liver injury; liver transplantation; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obesity; OxyELITE Pro

Indexed keywords

GARCINIA CAMBOGIA EXTRACT; GYMNENA SYLVESTRE EXTRACT; HERBACEOUS AGENT; HYDROXYCITRIC ACID; OXYELITE PRO; PLANT EXTRACT; RHODIOLA ROSEA EXTRACT; SINECATECHINS; UNCLASSIFIED DRUG; WITHANIA SOMNIFERA EXTRACT;

BODY WEIGHT DISORDER; BODY WEIGHT LOSS; CANCER RISK; CAUSALITY; CHINESE MEDICINE; COMORBIDITY; DIETARY SUPPLEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT; LIVER INJURY; METABOLIC DISORDER; MORBID OBESITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS;

EID: 85057583301     PISSN: None     EISSN: 23979070     Source Type: Journal    
DOI: 10.1002/jgh3.12057     Document Type: Review

References (51)

1. Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016; 39: 561–75. https://doi.org/10.1007/s4026401604278.
2. Shahbaz O, Mahajan S, Lewis JH. Highlights of drug- and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice? Exp. Opin. Drug Metab. Toxicol. 2017; 13: 935–51. https://doi.org/10.1080/17425255.2017.1362391 Cited 10 Nov 2017.
3. Brown A. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. Food Chem. Toxcol. 2017; 107: 472–501.
4. Teschke R, Andrade RJ. Editorial. Special issue “drug, herb, and dietary supplement hepatotoxicity”. Int. J. Mol. Sci. 2016; 17: 1488. https://doi.org/10.3390/ijms17091488 Cited 10 Nov 2017. Available from URL: http://www.mdpi.com/journal/ijms/special_issues/Hepatotoxicity.
5. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int. J. Mol. Sci. 2016; 17: 14. https://doi.org/10.3390/ijms17010014.
6. Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int. J. Mol. Sci. 2016; 17: 224. https://doi.org/10.3390/ijms17020224.
7. Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int. J. Mol. Sci. 2016; 17: 588. https://doi.org/10.3390/ijms17050588.
8. Avigan MI, Mozersky RP, Seeff LB. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int. J. Mol. Sci. 2016; 17: 331. https://doi.org/10.3390/ijms17030331.
9. Teschke R, Eickhoff A, Schwarzenboeck A et al. Clinical review: herbal hepatotoxicity and the call for systematic data documentation of individual cases. J. Liver Clin. Res. 2015; 2: 1008 Cited 10 Nov 2017. Available from URL: http://www.jscimedcentral.com/Liver/liver-2-1008.pdf.
10. Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur. J. Gastroenterol. Hepatol. 2013; 25: 1093–8. https://doi.org/10.1097/MCG.0b013e3283603e89.
11. Teschke R, Frenzel C, Schulze J, Schwarzenboeck A, Eickhoff A. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. World J. Hepatol. 2013; 5: 353–63.
12. Zambrone FAD, Corrêa CL, Sampaio do Amaral LM. A critical analysis of the hepatotoxicity cases described in the literature related to Herbalife products. Braz. J. Pharm. Sci. 2015; 51. Cited 10 Nov 2017. https://doi.org/10.1590/S1984-82502015000400004.
13. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease; the major impact in China. Hepatology. 2014; 60: 2099–108.
14. Younossi ZM, Stepanova M, Affendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9: 524–30.
15. Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W, Teschke R. Herbal traditional Chinese medicine and suspected liver injury: a prospective study. World J. Hepatol. 2017; 18: 1141–57. https://doi.org/10.4254/wjh.v9.i29.1141.
16. Cho JH, Oh DS, Hong SH et al. A nationwide study of the incidence rate of herb-induced liver injury in Korea. Arch. Toxicol. 2017; 91: 4009–15.
17. Vega M, Verma M, Beswick D et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf. 2017; 40: 783–7. https://doi.org/10.1007/s40264-017-0547-9.
18. GBD 2013 Obesity Collaboration. Global, regional and national prevalence of overweight and obesity in children and adults 1980–2013: a systematic analysis. Lancet. 2014; 384: 766–81.
19. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J. Am. Med. Assoc. 2003; 289: 76–9.
20. Marseglia L, Manti S, D'Angelo G et al. Oxidative stress in obesity: a critical component in human diseases. Int. J. Mol. Sci. 2015; 16: 378–400. https://doi.org/10.3390/ijms16010378.
21. Teschke R, Schulze J, Eickhoff A, Wolff A, Frenzel C. Mysterious Hawaii liver disease case—Naproxen overdose as cause rather than OxyELITE Pro? J. Liver Clin. Res. 2015; 2: 1013 Cited 10 Nov 2017. Available from URL: http://www.jscimedcentral.com/Liver/liver-2-1013.pdf.
22. Teschke R, Schwarzenboeck A, Frenzel C, Schulze J, Eickhoff A, Wolff A. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann. Hepatol. 2016; 15: 91–119 Cited 10 Nov 2017. Available from URL: http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTEGIDO%20(1).pdf.
23. Teschke R, Eickhoff A. The Honolulu liver disease cluster at the Medical Center: its mysteries and challenges. Int. J. Mol. Sci. 2016; 17: 476. https://doi.org/10.3390/ijms17040476.
24. Dhana K, Nano J, Ligthart S et al. Obesity and life expectancy with and without diabetes in adults aged 55 years and older in the Netherlands: a prospective cohort study. PLoS Med. 2016; 13: e1002086. https://doi.org/10.1371/journal.pmed.1002086.
25. Suzuki M, Willcox B, Willcox C. Okinawa Centenarian Study, 1976. Cited 10 Nov 2017. Available from URL: http://www.okicent.org/team.html
26. Chang Y, Jung HS, Cho J et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2016; 111: 1133–40. https://doi.org/10.1038/ajg.2016.178.
27. Targher G, Byrne CD. Obesity: metabolic healthy obesity and NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2016; 13: 442–4 Cited 10 Nov 2017. Available from URL: https://www.nature.com/articles/nrgastro.2016.104.
28. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 4: 1313–21.
29. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012; 107: 811–26. https://doi.org/10.1038/ajg.2012.128.
30. Cholankeril G, Wong RJ, Hu M et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig. Dis. Sci. 2017; 62: 2915–22.
31. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wimmer M. Fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84.
32. WHO. Obesity and Overweight. Fact Sheet, updated October 2017. Cited 10 Nov 2017. Available from URL: http://www.who.int/mediacentre/factsheets/fs311/en/
33. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124–31.
34. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018; 67: 123–133.
35. Roytman MM, Pörzgen P, Lee CL et al. Letter to the Editor: outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am. J. Gastroenterol. 2014; 109: 1296–8.
36. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017; 65: 1363–73.
37. Teschke R, Danan G. Review article: diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016; 39: 729–44. https://doi.org/10.1007/s40264-016-0423-z.
38. Teschke R, Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Exp. Opin. Drug Metab. Toxicol. 2017; 13: 425–38.
39. Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch. Toxicol. 2015; 89: 1175–91.
40. Teschke R, Zhang L, Long H et al. Traditional Chinese medicine and herbal hepatotoxicity: a tabular compilation of reported cases. Ann. Hepatol. 2015; 14: 7–19.
41. Sarma DN, Barrett ML, Chavez ML et al. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf. 2008; 31: 469–84.
42. Frank J, George TW, Lodge JK et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J. Nutr. 2009; 139: 58–62. https://doi.org/10.3945/jn.108.096412.
43. Isomura T, Suzuki S, Origasa H et al. Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials. Eur. J. Clin. Nutr. 2016; 70: 1221–9. https://doi.org/10.1038/ejcn.2016.78.
44. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Exp. Opin. Drug Metab. Toxicol. 2009; 5: 843–60.
45. Teschke R, Zhang L, Melzer L, Schulze J, Eickhoff A. Green tea extract and the risk of drug-induced liver injury. Exp. Opin. Drug Metab. Toxicol. 2014; 10: 1663–76. https://doi.org/10.1517/17425255.2014.971011.
46. Elinav E, Pinkser G, Safadi R et al. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J. Hepatol. 2007; 47: 514–20.
47. Schoepfer AM, Engel A, Fattinger K et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J. Hepatol. 2007; 47: 521–6.
48. Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife® nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 2009; 50: 111–17.
49. Jóhannsson M, Ormarsdóttir S, Olafsson S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid. 2010; 96: 167–72 [Article in Icelandic].
50. Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J. Gastroenterol. 2008; 14: 6999–7004.
51. Araujo JL, Worman HJ. Acute liver injury associated with new formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep. 2015; 2015. https://doi.org/10.1136/bcr-2015-210303.